NCT03356730

Brief Summary

  1. 1.Title
  2. 2.Executive team
  3. 3.Research line
  4. 4.Summary
  5. 5.Research problem
  6. 6.Justification
  7. 7.Literature review
  8. 8.Objectives
  9. 9.Materials and methods
  10. 10.Dissemination of knowledge generated
  11. 11.Schedule of activities
  12. 12.Budget
  13. 13.References
  14. 14.Annexes

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Nov 2017

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 17, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

November 19, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 29, 2017

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2018

Completed
Last Updated

November 29, 2017

Status Verified

November 1, 2017

Enrollment Period

1 month

First QC Date

August 17, 2017

Last Update Submit

November 28, 2017

Conditions

Keywords

ImplantsVitamin DOsseointegrationHistomorphometric

Outcome Measures

Primary Outcomes (1)

  • Percentage of bone implant contact

    Histomorphometry will be used as a method of analysis. It will evaluate the initial stage of osseointegration in the two groups, relating it to insufficiency / deficiency and sufficiency of vitamin D. The percentage of bone implant contact, defined as the amount of mineralized bone in direct contact with the surface of the miniimplant, will be evaluated.

    2 months

Secondary Outcomes (1)

  • Serum levels of vitamin D (ng/ml)

    2 months

Study Arms (2)

Arm vitamin D

EXPERIMENTAL

Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)

Drug: Vitamin D

Arm placebo

PLACEBO COMPARATOR

Placebo for 2 months (10 drops after lunch)

Other: Placebo

Interventions

Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation. Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows: • 5,000 IU / day - 10 drops per day for two months.

Arm vitamin D
PlaceboOTHER

Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo. Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows: • 10 drops per day for two months.

Arm placebo

Eligibility Criteria

Age25 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of both sexes;
  • No medical, temporary or intra-oral contraindications;
  • Good general health;
  • Need of implant in the maxilla in the posterior region (with a minimum of 5 mm of bone height visualized radiographically) or in mandible in posterior region;
  • With vitamin D deficiency / deficiency (considering serum level of ≥ 15 ng / ml at ≤ 25 ng / ml).

You may not qualify if:

  • Medical, temporary or intrabuccal contraindications;
  • Smokers;
  • Use of corticoid;
  • Post-operative of bariatric surgery;
  • Bone height less than 5mm;
  • Need for maxillary sinus lift;
  • Vitamin supplementation D.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Isadora Rinaldi

Rondinha, Rio Grande do Sul, 99590-000, Brazil

RECRUITING

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

Vitamin D

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Maria Salete Sandini Linden

    Universidade de Passo Fundo

    STUDY DIRECTOR

Central Study Contacts

Isadora Rinaldi

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Masking for placebo or vitamin D use
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a clinical research study, characterized by a randomized, double-blind, placebo-controlled trial.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Master Student

Study Record Dates

First Submitted

August 17, 2017

First Posted

November 29, 2017

Study Start

November 19, 2017

Primary Completion

December 30, 2017

Study Completion

April 30, 2018

Last Updated

November 29, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will share

The individual participants data (IPD) will be available in the dental records including complementary exams, allowing the access of other researchers during the research.

Locations